Skip to main content

Table 1 Studies included in the cumulative NMA for overall survival

From: Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

  2008 2010 2012 2014 2016
RCTs: 100% HER2+ ALTTO
(Piccart-Gebhart 2016) [66]
BCIRG 006
(Slamon 2011) [44]
BCIRG 006
(Slamon 2011) [44]
BCIRG 006
(Slamon 2015) [21]
FNCLCC-PACS 04
(Spielmann 2009) [67]
FNCLCC-PACS 04
(Spielmann 2009) [67]
FNCLCC-PACS 04
(Spielmann 2009) [67]
FNCLCC-PACS 04
(Spielmann 2009) [67]
HannaH
(Jackisch 2016) [68]
HERA
(Smith 2007) [69]
HERA
(Smith 2007) [69]
HERA
(Gianni 2011) [19]
HERA
(Goldhirsch 2013) [64]
HERA
(Goldhirsch 2013) [64]
HORG
(Mavroudis 2015) [70]
NCCTG N9831 and NSABP B-31
(Romond 2005) [18]
NCCTG N9831 and NSABP B-31
(Romond 2005) [18]
NCCTG N9831 andNSABP B-31
(Perez 2011) [71]
NCCTG N9831 and NSABP B-31
(Perez 2014) [51]
NCCTG N9831 and NSABP B-31
(Perez 2014) [51]
NeoALTTO
(de Azambuja 2014) [72]
NeoALTTO
(de Azambuja 2014) [72]
NOAH
(Gianni 2010) [73]
NOAH
(Gianni 2010) [73]
NOAH
(Gianni 2014) [20]
NOAH
(Gianni 2014) [20]
NSABP B-41
(Robidoux 2016) [74]
PHARE
(Pivot 2013) [75]
PHARE
(Pivot 2013) [75]
RCTs: HER2+ subgroups BCIRG 001
(Mackey 2013) [76]
BCIRG 001
(Mackey 2013) [76]
Boccardo 2010 [77] Boccardo 2010 [77] Boccardo 2010 [77] Boccardo 2010 [77]
BR9601 and NEAT
(Earl 2012) [78]
BR9601 and NEAT
(Earl 2012) [78]
BR9601 and NEAT
(Earl 2012) [78]
Colozza 2005 [79] Colozza 2005 [79] Colozza 2005 [79] Colozza 2005 [79] Colozza 2005 [79]
Del Mastro 2015 [80]
E1199
(Sparano 2008) [81]
E1199
(Sparano 2008) [81]
E1199
(Sparano 2008) [81]
E1199
(Sparano 2008) [81]
E1199
(Sparano 2008) [81]
E2198
(Schneider 2015) [82]
FinHer
(Joensuu 2009) [83]
FinHer
(Joensuu 2009) [83]
FinHer
(Joensuu 2009) [83]
FinHer
(Joensuu 2009) [83]
FinXX
(Joensuu 2014) [84]
FinXX
(Joensuu 2014) [84]
GeparTrio
(von Minckwitz 2013) [85]
GeparTrio
(von Minckwitz 2013) [85]
GONO-MIG-1
(Del Mastro 2005) [86]
GONO-MIG-1
(Del Mastro 2005) [86]
GONO-MIG-1
(Del Mastro 2005) [86]
GONO-MIG-1
(Del Mastro 2005) [86]
GONO-MIG-1
(Del Mastro 2005) [86]
Miles 1999 [87] Miles 1999 [87] Miles 1999 [87] Miles 1999 [87] Miles 1999 [87]
Rocca 2014 [88] Rocca 2014 [88]
TEACH
(Goss 2013) [89]
TEACH
(Goss 2013) [89]
  UNICANCER-PACS-01
(Coudert 2012) [90]
UNICANCER-PACS-01
(Coudert 2012) [90]
UNICANCER-PACS-01
(Coudert 2012) [90]
Observational Bayraktar 2012 [91] Bayraktar 2012 [91] Bayraktar 2012 [91]
Gonzalez-Angulo 2015 [92]
Seferina 2015 [93]
  1. HER2+ human epidermal growth factor receptor 2-positive, NMA network meta-analysis, OS overall survival, RCT randomized controlled trial